search
Back to results

Ureteroscopy With and Without Safety Guidewire

Primary Purpose

Urolithiasis

Status
Withdrawn
Phase
Not Applicable
Locations
Norway
Study Type
Interventional
Intervention
Ureteroscopy with and without safety guidewire
Sponsored by
Helse-Bergen HF
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Urolithiasis focused on measuring Ureteroscopy

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients with urolithiasis planned for ureterorenoscopic treatment

Sites / Locations

  • Helse Bergen HF, Haukeland University Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

B - without SGW

A - with SGW

Arm Description

Ureteroscopy without SGW in place.

Ureteroscopy with SGW in place.

Outcomes

Primary Outcome Measures

Stone free-rate

Secondary Outcome Measures

Hospital stay
Complication rate
Operating time

Full Information

First Posted
May 4, 2010
Last Updated
March 31, 2015
Sponsor
Helse-Bergen HF
search

1. Study Identification

Unique Protocol Identification Number
NCT01117688
Brief Title
Ureteroscopy With and Without Safety Guidewire
Official Title
Ureteroscopy With and Without Safety Guidewire:. A Prospective, Randomized Study of the Results of Endoscopic Treatment of Urolithiasis.
Study Type
Interventional

2. Study Status

Record Verification Date
June 2011
Overall Recruitment Status
Withdrawn
Why Stopped
Withdrawn. Not enough time to go through with the study.
Study Start Date
May 2010 (undefined)
Primary Completion Date
December 2012 (Anticipated)
Study Completion Date
December 2012 (Anticipated)

3. Sponsor/Collaborators

Name of the Sponsor
Helse-Bergen HF

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to investigate the impact of a safety guidewire (SGW) on the results of ureteroscopy for urolithiasis. Study hypothesis: Routine use of SGW has no impact on the results of ureteroscopic treatment of urolithiasis.
Detailed Description
The use of SGW is generally recommended at any ureteroscopic procedure in order to facilitate the introduction of the endoscope and to secure placement of internal tubes for drainage of urine after the procedure. However, SGW may be an obstacle to efficient disintegration and retraction of calculi in the narrow ureter. The intention of this study is to compare the results of endoscopic stone treatment with and without the use of SGW.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Urolithiasis
Keywords
Ureteroscopy

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
B - without SGW
Arm Type
Active Comparator
Arm Description
Ureteroscopy without SGW in place.
Arm Title
A - with SGW
Arm Type
Active Comparator
Arm Description
Ureteroscopy with SGW in place.
Intervention Type
Procedure
Intervention Name(s)
Ureteroscopy with and without safety guidewire
Intervention Description
In study arm A - with SGW, endoscopic treatment is performed with a safety guidewire in place. In study arm B - without SGW, the ureteroscopy is performed without SGW.
Primary Outcome Measure Information:
Title
Stone free-rate
Time Frame
3 months after treatment
Secondary Outcome Measure Information:
Title
Hospital stay
Time Frame
Up to 1 week after the operation
Title
Complication rate
Time Frame
Until 3 months after the procedure
Title
Operating time
Time Frame
Up to 1 day after the surgery

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with urolithiasis planned for ureterorenoscopic treatment
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Øyvind Ulvik, MD
Organizational Affiliation
Helse Bergen HF, Haukeland University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Helse Bergen HF, Haukeland University Hospital
City
Bergen
ZIP/Postal Code
5021
Country
Norway

12. IPD Sharing Statement

Learn more about this trial

Ureteroscopy With and Without Safety Guidewire

We'll reach out to this number within 24 hrs